Markets:

Overview

News

Currencies

International

Treasuries

Century Therapeutics, Inc. - Common Stock (NQ:IPSC)

0.5301 -0.0122 (-2.25%)

Streaming Delayed Price Updated: 10:42 AM EST, Dec 2, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Century Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

Century Therapeutics to Present at the Chardan 7th Annual Genetic Medicines Conference

September 26, 2023

From Century Therapeutics, Inc.

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For August 28, 2023 ↗

August 28, 2023

Via Benzinga

Workday To Rally Around 20%? Here Are 10 Other Analyst Forecasts For Monday ↗

August 28, 2023

Truist Securities raised the price target for Church & Dwight Co., Inc. (NYSE: CHD) from $95 to $105. Truist Securities analyst Bill Chappell upgraded the stock from Hold to Buy. Church & Dwight shares...

Via Benzinga

Century Therapeutics: Q1 Earnings Insights ↗

May 11, 2023

Via Benzinga

Analyst Ratings for Century Therapeutics ↗

April 13, 2023

Via Benzinga

These Analysts Slash Their Forecasts On Century Therapeutics After Weak Q2 Results ↗

August 10, 2023

Century Therapeutics, Inc. (NASDAQ: IPSC) reported weaker-than-expected second-quarter results.

Via Benzinga

Century Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates

August 09, 2023

From Century Therapeutics, Inc.

Via GlobeNewswire

Century Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates

May 11, 2023

From Century Therapeutics, Inc.

Via GlobeNewswire

Century Therapeutics to Present at Chardan’s 7th Annual Genetic Medicines & Cell Therapy Manufacturing Virtual Summit

April 17, 2023

From Century Therapeutics, Inc.

Via GlobeNewswire

Century Therapeutics's Return On Capital Employed Overview ↗

March 20, 2023

Via Benzinga

Where Century Therapeutics Stands With Analysts ↗

March 16, 2023

Via Benzinga

8 Analysts Have This to Say About Century Therapeutics ↗

January 06, 2023

Via Benzinga

Century Therapeutics Announces Leadership Changes

April 12, 2023

From Century Therapeutics, Inc.

Via GlobeNewswire

Century Therapeutics Reports Full Year 2022 Financial Results and Provides Business Updates

March 16, 2023

From Century Therapeutics, Inc.

Via GlobeNewswire

Century Therapeutics to Present at the AACR Annual Meeting 2023

March 15, 2023

From Century Therapeutics, Inc.

Via GlobeNewswire

Century Therapeutics to Present at Upcoming Investor Conferences

February 21, 2023

From Century Therapeutics, Inc.

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For December 27, 2022 ↗

December 27, 2022

Via Benzinga

Century Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 ELiPSE-1 Trial Evaluating CNTY-101 in Relapsed or Refractory CD19 Positive B-cell Lymphomas

February 08, 2023

From Century Therapeutics, Inc.

Via GlobeNewswire

Century Therapeutics to Present at Upcoming Investor Conferences

February 01, 2023

From Century Therapeutics, Inc.

Via GlobeNewswire

How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?

January 25, 2023

Five biotechs have already issued layoffs in 2023. Many seem to have good potential, but time will tell if the shifts create the value analysts anticipate.

Via MarketBeat

Topics Workforce

Stocks That Hit 52-Week Lows On Thursday ↗

January 19, 2023

On Thursday, 29 stocks made new 52-week lows.

Via Benzinga

5 Health Care Stocks That Are Diving - And May Rally ↗

January 19, 2023

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

January 12, 2023

On Thursday, 13 stocks hit new 52-week lows.

Via Benzinga

Top 5 Health Care Stocks That May Surge ↗

January 10, 2023

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Via Benzinga

CRISPR Layoffs 2023: Job Cuts Hit Gene-Editing Stocks FATE, TCRR, IPSC ↗

January 06, 2023

Gene-editing stocks have not been immune when it comes to job losses and workforce reductions. Here are a few of the latest.

Via InvestorPlace

Century Therapeutics Announces Internal Portfolio Prioritization, Analyst Views It As Incrementally Positive ↗

January 06, 2023

Via Benzinga

Century Therapeutics Announces Internal Portfolio Prioritization to Extend Cash Runway Into 2026

January 05, 2023

From Century Therapeutics, Inc.

Via GlobeNewswire

Century Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 04, 2023

From Century Therapeutics, Inc.

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023 ↗

January 05, 2023

Via Benzinga

Arcus Biosciences, FuelCell Energy And Some Other Big Stocks Moving Lower On Tuesday ↗

December 20, 2022

U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Tuesday. Here are some big stocks recording losses in today’s session.

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.